All In Biotech

Drug Trial Radar · NCT05733741

Preservative-free Topical Anesthetics for Post-PRK Pain

Preservative-free Topical Anesthetics for the Management of Postoperative Pain Following Photorefractive Keratectomy

Last checked: Nov 20, 2026Latest source record: May 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

70

Actual

Start

Jan 30, 2023

Primary completion

Apr 15, 2023

Study completion Apr 15, 2023

Sponsor

Lead sponsor
Assiut UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 17, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this interventional comparative study is to assess the efficacy and safety of a novel regimen of preservative-free unit-dose topical anesthetics for controlling early postoperative pain following single-step transepithelial PRK surgery. The main research questions to answer are: * Question 1: Are topical anesthetics effective in reducing post-PRK pain? * Question 2: Are short-term topical anesthetics toxic to the cornea? * Question 3: How to prevent abuse of topical anesthetics by patients at home? Participants were planned to undergo a bilateral single-step transepithelial PRK surgery to correct their refractive errors and received a standard post-PRK treatment regimen for both eyes. Additionally, one eye was offered a preservative-free topical anesthetic as an experimental group and the other eye was offered a preservative-free artificial tear as a control group.

Conditions

  • Myopia

Interventions

  • Preservative-free Benoxinate hydrochloride 0.4% (Benoxidia unit-dose vials [UD], Orchidia pharmaceutical Ind., Egypt)Drug

    For each patient, one eye was treated with preservative-free Benoxinate hydrochloride 0.4%. The prescribed regimen comprises of the instillation of one drop immediately, 2, 4, 6 and 8 hours after the end of surgery. Every patient was given 5 UD vials only of preservative-free Benoxinate hydrochloride 0.4% at each follow up visit for the next postoperative day usage administered 5 times daily (every 3 hours while awake) for the first 3 postoperative days giving clear instructions to immediately discard the vial after single use.

  • Preservative-free Sodium hyaluronate 0.2% (Polyfresh unit-dose vials [UD], Orchidia pharmaceutical Ind., Egypt).Drug

    The other eye was treated with preservative-free Sodium hyaluronate 0.2%. The prescribed regimen comprises of the instillation of one drop immediately, 2, 4, 6 and 8 hours after the end of surgery. Every patient was given 5 UD vials only of preservative-free Sodium hyaluronate 0.2% at each follow up visit for the next postoperative day usage administered 5 times daily (every 3 hours while awake) for the first 3 postoperative days giving clear instructions to immediately discard the vial after single use.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Postoperative pain score on the verbal rating scale (VRS)Time frame: 1 week
  2. Postoperative pain score on the visual analogue scale (VAS)Time frame: 1 week

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tiba Eye Center

    Asyut, Egypt

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.